Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial

Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial

Statins are the accepted standard for lowering low-density lipoprotein-cholesterol (LDLC). However, 5%-10% of statin-treated patients report intolerance, mostly due to musclerelated adverse effects. There are challenges to objective identification of patients with statin intolerance. Evolocumab is a...

Ամբողջական նկարագրություն

Մատենագիտական մանրամասներ
Հիմնական հեղինակներ: Nissen, SE, Dent-Acosta, RE, Rosenson, RS, Stroes, E, Sattar, N, Mancini, GBJ, Ballantyne, CM, Catapano, A, Gouni-Berthold, I, Stein, EA, Xue, A, Wasserman, SM, Scott, R, Preiss, D, Thompson, PD
Ձևաչափ: Journal article
Լեզու:English
Հրապարակվել է: Wiley 2016

Նմանատիպ նյութեր